Suzhou Chunghwa Chemical & Pharmaceutical Industrial Co. Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation sacubitril-valsartan sodium tablets (specifications: 100 mg based on sacubitril-valsartan (sacubitril 49 mg/valsartan 1 mg), produced by Suzhou Sinochem Pharmaceutical Industry Co., Ltd.) and the reference preparation sacubitril-valsartan sodium tablets (Noxinto®, specifications: 100 mg based on sacubitril-valsartan (sacubitril 49 mg/valsartan 51 mg), produced by Novartis Farma S.p.A., licensed by Novartis Pharma SchweizAG) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. The secondary purpose of the study is to study the safety of the test preparation sacubitril-valsartan sodium tablets and the reference preparation sacubitril-valsartan sodium tablets in healthy adult subjects after a single oral administration in the fasting and fed state.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, the pharmacokinetic behavior of the test preparation Diacerein Capsules (Specification: 50mg, Manufacturer: Suzhou Sinochem Pharmaceutical Industry Co., Ltd.) and the reference preparation Diacerein Capsules (Specification: 50mg, Trade Name: Ambitin®, Licensee: TRB Pharma S.A.) in healthy subjects after a single oral administration under fasting and postprandial conditions was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation Diacerein Capsules and the reference preparation Diacerein Capsules (Trade Name: Ambitin®) in healthy subjects.

Main research purpose Evaluation of the test preparation (specification: 20 mg, Sponsor: Suzhou Sinochem Pharmaceutical Industry Co., Ltd.) and the reference preparation (Specification: 20 mg, Suzhou Sinochem Pharmaceutical Industry Co., Ltd.) as a single single-dose oral oral dose of texagliptin hydrobromide tablets in Chinese healthy adult subjects under fasting and postprandial conditions. Trade name: Tenelia®, strength: 20 mg, license holder: Mitsubishi Tanbei Co., Ltd.) pharmacokinetic characteristics and bioequivalence. Secondary research purpose To study the safety of the test preparation (specification: 20mg) and reference preparation (trade name: Tenelia®, specification: 20mg) of titagliptin hydrobromide tablets in healthy Chinese adult subjects.